Patient and Provider Variables Associated with Systemic Treatment of Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Patient and Provider Variables Associated with Systemic Treatment of Advanced Prostate Cancer

Published:2019-07 Issue:4 Volume:6 Page:234-242
ISSN:2352-0779
Container-title:Urology Practice
language:en
Short-container-title:Urology Practice

Author:

Caram Megan E. V.¹²³,Wang Shikun⁴,Tsao Phoebe¹,Griggs Jennifer J.¹²⁵,Miller David C.⁶,Hollenbeck Brent K.⁶,Lin Paul²,Mukherjee Bhramar⁴

Affiliation:

1. Department of Internal Medicine, Division of Hematology/Oncology, School of Public Health, University of Michigan, Ann Arbor, Michigan

2. Institute for Health Policy and Innovation, School of Public Health, University of Michigan, Ann Arbor, Michigan

3. University of Michigan Medical School, VA Health Services Research & Development, Center for Clinical Management and Research, VA Ann Arbor Healthcare System, School of Public Health, University of Michigan, Ann Arbor, Michigan

4. Department of Biostatistics and Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan

5. Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, Michigan

6. Department of Urology, School of Public Health, University of Michigan, Ann Arbor, Michigan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference26 articles.

1. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

4. Abiraterone and Increased Survival in Metastatic Prostate Cancer

5. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to Editorial Comment: Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study;JU Open Plus;2024-04

2. Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study;JU Open Plus;2024-02-29

3. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the “Real World”? A Systematic Review;European Urology Oncology;2024-02

4. Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System;JCO Oncology Practice;2024-01

5. Drug costs: acquisition costs are critical but not the entire story of financial toxicity;BJU International;2023-06-11